Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors

Affiliations

Comment

Y Fujisawa. Br J Dermatol. 2018 Jul.

. 2018 Jul;179(1):224-225.

doi: 10.1111/bjd.16689. Epub 2018 May 7.

No abstract available

Comment in

Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors.
Machet L, Zaragoza J, Finon A, Garnier M, Maillard H, Caille A. Machet L, et al. Br J Dermatol. 2018 Jul;179(1):224. doi: 10.1111/bjd.16675. Epub 2018 May 8. Br J Dermatol. 2018. PMID: 29660775 No abstract available.

Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Tanaka R, Yamaguchi K, Nonomura Y, Hirai I, Furudate S, Okuhira H, Imafuku K, Aoki M, Matsushita S. Fujisawa Y, et al. Br J Dermatol. 2018 Jul;179(1):213-215. doi: 10.1111/bjd.16427. Epub 2018 Apr 24. Br J Dermatol. 2018. PMID: 29405254 No abstract available.